USPTO Examiner BRADLEY CHRISTINA - Art Unit 1654

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18949272FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASESNovember 2024June 2025Allow721NoNo
18829566CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRASSeptember 2024November 2024Allow200YesNo
18821027AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALTAugust 2024May 2025Allow820NoNo
18640964AQUEOUS SOLUTION COMPRISING A GLUTATHIONE SALTApril 2024May 2024Allow100YesNo
18431596FIBROIN-DERIVED PROTEIN COMPOSITIONFebruary 2024March 2025Allow1310NoNo
18392459STABLE ASCORBIC ACID COMPOSITIONS AND METHODS OF USING SAMEDecember 2023February 2025Allow1410NoNo
18518880COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTSNovember 2023January 2025Abandon1401NoNo
18518879COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTSNovember 2023January 2025Abandon1401NoNo
18476587GLUCAGON ANALOGUES AS LONG-ACTING GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITISSeptember 2023December 2024Allow1410NoNo
18460024SUPRAMOLECULAR FILAMENTOUS ASSEMBLIES FOR PROTEIN PURIFICATIONSeptember 2023March 2025Allow1820NoNo
18452479PEPTIDIC DIAGNOSTIC COMPOSITIONSAugust 2023March 2025Allow1911YesNo
18363810THE PREPARATION OF CERAMIDE CONJUGATES AND DERIVATIVES OF SPHINGOLIPID ANALOGUESAugust 2023August 2024Allow1300NoNo
18355240SYNTHETIC LUNG SURFACTANT WITH ENHANCED STABILITY AND EFFECTIVENESSJuly 2023February 2025Abandon1920NoNo
18347246LONG ACTING PEPTIDE TYROSINE TYROSINE (PYY) ANALOGS AND METHODS OF USEJuly 2023June 2024Allow1110NoNo
18203371DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUNDMay 2023October 2024Allow1700NoNo
18320638USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISKMay 2023March 2024Abandon1010NoNo
18142470METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITIONMay 2023July 2024Allow1420NoNo
18296801USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISKApril 2023April 2024Abandon1310NoNo
18187639De Novo Design of Potent and Selective Interleukin MimeticsMarch 2023October 2024Allow1911NoNo
18121384COLLAGEN COMPOSITIONS AND USES FOR BIOMATERIAL IMPLANTSMarch 2023June 2025Abandon2750NoNo
18115744DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODSFebruary 2023March 2025Allow2430YesNo
18168438STABLE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAMEFebruary 2023February 2024Allow1200NoNo
18164515COMPOSITION FOR IMPROVING HAIR HEALTHFebruary 2023March 2025Allow2540YesNo
18152624COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOFJanuary 2023April 2024Abandon1601NoNo
181502461,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling PathwaysJanuary 2023April 2025Allow2731NoNo
18013389V1A Receptor Partial Agonist and Method of UseDecember 2022April 2025Allow2811YesNo
18068838METHODS AND SYSTEMS FOR SOLID PHASE PEPTIDE SYNTHESISDecember 2022March 2024Allow1510NoNo
18083811MIC-1 COMPOUNDS AND USE THEREOFDecember 2022February 2024Allow1411NoNo
18084155TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER, INFECTIONS AND AUTOIMMUNE DISORDERSDecember 2022September 2024Allow2121NoNo
17987137COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF LAR FAMILY PHOSPHATASESNovember 2022August 2024Allow2111NoNo
18053701PTH Compounds with Low Peak-To-Trough RatiosNovember 2022September 2023Allow1110YesNo
18050964TARGETED DELIVERY SYSTEM AND METHODS OF USE THEREFOROctober 2022September 2024Allow2210YesNo
18048262METHOD AND COMBINATION FOR THE SUPPRESSION OF COVID-19 VIRUSOctober 2022March 2025Allow2941YesNo
17964903DILEUCINE COMPOSITIONS AND METHODS OF USE THEREOF FOR FAT LOSSOctober 2022June 2024Abandon2020NoNo
17938861STABLE ASCORBIC ACID COMPOSITIONS AND METHODS OF USING SAMEOctober 2022September 2023Allow1210NoNo
17912907CYCLOTIDES IN COMBINATION WITH KAPPA OPIOID RECEPTOR LIGANDS FOR MS THERAPYSeptember 2022April 2025Abandon3110NoNo
17932230COMPOSITIONS AND METHODS FOR TREATING COLLAGEN-MEDIATED DISEASESSeptember 2022June 2024Abandon2120NoNo
17898994HMGB1 ANTAGONIST TREATMENT OF SEVERE SEPSISAugust 2022October 2023Allow1410NoNo
17898384Anti-CD70 Antibody Drug ConjugatesAugust 2022October 2023Allow1400NoNo
17880271METHODS FOR REDUCING CD36 EXPRESSIONAugust 2022March 2025Abandon3120NoYes
17814818OPHTHALMIC COMPOSITIONS COMPRISING CICLOSPORINJuly 2022April 2024Abandon2020NoNo
17864829CYCLOPEPTIDE AND METHOD FOR PREPARING THE SAMEJuly 2022January 2025Allow3010YesNo
17861353VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSIONJuly 2022December 2024Abandon2911NoNo
17851615SYNTHETIC LUNG SURFACTANT WITH ENHANCED STABILITY AND EFFECTIVENESSJune 2022August 2023Abandon1410NoNo
17837736PEPTIDE ANALOGSJune 2022June 2024Allow2410NoNo
17783224MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANTJune 2022March 2025Allow3310NoNo
17831017PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDEJune 2022October 2024Allow2821NoNo
17725340IMMUNOMODULATORSApril 2022October 2023Allow1810NoNo
17768356TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASEApril 2022April 2025Allow3710NoNo
17767508TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIESApril 2022February 2025Allow3510YesNo
17762873NOVEL POLYMORPH FORM OF (R)-2-[2-AMINO-3-(INDOL-3-YL)PROPIONYLAMINO]-2-METHYLPROPIONIC ACID AND USES THEREOFMarch 2022September 2023Allow1820YesNo
17761753Method of TreatmentMarch 2022May 2025Abandon3801NoNo
17698553De Novo Design of Potent and Selective Interleukin MimeticsMarch 2022September 2024Allow3000NoNo
17760596SUBCUTANEOUSLY INJECTABLE INSULIN AND GLUCAGON FORMULATIONS AND METHODS OF ADMINISTRATIONMarch 2022May 2025Abandon3801NoNo
17640679OPHTHALMIC COMPOSITION FOR THE TREATMENT OF UVEITISMarch 2022May 2025Allow3910YesNo
17684267COMPOSITIONS AND USES OF ANTIMICROBIAL MATERIALS WITH TISSUE-COMPATIBLE PROPERTIESMarch 2022February 2024Allow2320NoNo
17634490THERAPEUTIC PEPTIDESFebruary 2022April 2025Abandon3801NoNo
17634499THERAPEUTIC PEPTIDESFebruary 2022April 2025Abandon3801NoNo
17629501GLUCOSE-RESPONSIVE INSULIN CONJUGATESJanuary 2022May 2025Abandon3911NoNo
17628552ANTIBACTERIAL PEPTIDE DERIVED FROM ERYTHROCULTER ILISHAEFORMIS AND USE THEREOFJanuary 2022December 2024Allow3510NoNo
17648137GHRH ANTAGONISTS FOR USE IN A METHOD OF TREATING SARCOIDOSISJanuary 2022April 2025Allow3820YesNo
17624830A TEIXOBACTIN ANALOGUE AND USE THEREOFJanuary 2022May 2025Allow4020NoNo
17560420STABLE COMPOSITIONS OF PEGYLATED CARFILZOMIB COMPOUNDSDecember 2021July 2024Abandon3111NoNo
17619918ROMO1-DERIVED ANTIMICROBIAL PEPTIDES INCLUDING LYSINE SUBSTITUTION AND VARIANTS THEREOFDecember 2021July 2024Allow3120YesNo
17619913ROMO1-DERIVED ANTIMICROBIAL PEPTIDES AND VARIANTS THEREOFDecember 2021April 2024Allow2820NoNo
17619502STABLE FORMULATION OF CETRORELIXDecember 2021March 2025Abandon3910NoNo
17610783Cyclic Peptide Compound Simulating Natural Product Structure, And Method For Preparation ThereofNovember 2021June 2024Allow3111YesNo
17521146STREPTAVIDIN MUTEINS AND METHODS OF USING THEMNovember 2021March 2024Abandon2811NoNo
17594454PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MOLECULESOctober 2021March 2025Allow4111YesNo
17500307METHOD OF TREATING AMD IN PATIENTS REFRACTORY TO ANTI-VEGF THERAPYOctober 2021May 2023Abandon1910NoNo
17500315METHOD OF TREATING CONDITIONS OF THE EYE WITH AN ANTI-VEGF DARPINOctober 2021May 2023Abandon1910NoNo
17499640LIPOCALIN MUTEINS WITH BINDING AFFINITY FOR LAG-3October 2021May 2023Allow1901NoNo
17487904STAPLED PEPTIDE INHIBITORS OF NEMO AS POTENTIAL ANTI-INFLAMMATORY AND ANTI-CANCER DRUGSSeptember 2021September 2023Allow2411NoNo
17599402BRANCHED DEGRADABLE POLYETHYLENE GLYCOL BINDERSeptember 2021March 2025Allow4221YesNo
17442765PIEZOELECTRIC PEPTIDE-BASED MATERIALS AND PIEZOELECTRIC DEVICES CONTAINING SAMESeptember 2021August 2024Allow3441YesNo
17481102PEPTIDE LINKER AND COMBINATION FOR PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGENSeptember 2021November 2022Allow1410YesNo
17473731De Novo Design of Potent and Selective Interleukin MimeticsSeptember 2021December 2022Allow1521NoNo
17472393VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSIONSeptember 2021April 2024Allow3121YesNo
17471543USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISKSeptember 2021August 2023Abandon2310NoNo
17459680COMPOSITIONS AND METHODS FOR DIAGNOSING AND/OR TREATING KIDNEY INJURYAugust 2021February 2024Allow3020NoNo
17400190FUNCTIONALIZED PEPTIDES AS ANTIVIRAL AGENTSAugust 2021February 2023Abandon1810NoNo
17429667WS-635 USES THEREOF IN MEDICINEAugust 2021December 2024Allow4110YesNo
17429887METHOD FOR TREATING PREECLAMPSIAAugust 2021November 2024Abandon4010NoNo
17310506NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAINAugust 2021January 2025Allow4241YesNo
17310468ANTIMICROBIAL PEPTIDE FOR ONYCHOMYCOSISAugust 2021December 2024Abandon4010NoNo
17428604Dry Pharmaceutical Formulations of CNP ConjugatesAugust 2021March 2025Allow4421YesNo
17428608Liquid Pharmaceutical Formulations of PTH ConjugatesAugust 2021April 2025Allow4421YesNo
17427475METHODS AND COMPOSITIONS FOR IL10 SIGNALING ANTAGONISMJuly 2021December 2024Abandon4101NoNo
17426756USE OF IGFBP7 FOR TREATING MALARIAJuly 2021May 2024Allow3400NoNo
17380311ANGIOTENSIN II ALONE OR IN COMBINATION FOR THE TREATMENT OF HYPOTENSIONJuly 2021November 2022Allow1631YesNo
17368464RECONSTITUTED HIGH DENSITY LIPOPROTEIN FORMULATION AND PRODUCTION METHOD THEREOFJuly 2021March 2023Allow2010NoNo
17420110DUAL AGONIST GLP-1 AND NEUROTENSIN FUSION PEPTIDEJune 2021January 2025Abandon4321YesNo
17360674FIBROIN-DERIVED PROTEIN COMPOSITIONJune 2021September 2023Allow2711NoNo
17359202STABLE SUSTAINED RELEASE THERAPEUTIC COMPOSITIONS IN APROTIC POLAR SOLVENTS AND METHODS OF MANUFACTURING THE SAMEJune 2021February 2024Allow3221YesNo
17418684PHARMACEUTICAL COMPOSITION COMPRISING PIBF PROTEIN AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASEJune 2021April 2024Allow3410NoNo
17355022MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOFJune 2021September 2024Allow3922NoNo
17415782USE OF TRANSFERRIN, TRANSFERRIN RECEPTOR AND ANTIBODY THEREOF IN PREPARATION OF ANTI-SARS-CoV-2 DRUGJune 2021April 2025Abandon4540NoNo
17415190Binding Domain Mapping and Compounds, Compositions, Complexes, Methods, and Kits Related TheretoJune 2021February 2025Allow4421NoNo
17350280COLLAGEN HYDROLYSATE FOR USE WITH SKIN DISORDERS AND INTESTINAL DISORDERSJune 2021September 2024Allow3911NoNo
17350170COMPOSITIONS AND METHODS FOR TREATING VIRUS INFECTIONJune 2021October 2022Allow1610YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BRADLEY, CHRISTINA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
3
(75.0%)
Examiner Reversed
1
(25.0%)
Reversal Percentile
36.5%
Lower than average

What This Means

With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
44
Allowed After Appeal Filing
5
(11.4%)
Not Allowed After Appeal Filing
39
(88.6%)
Filing Benefit Percentile
12.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 11.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BRADLEY, CHRISTINA - Prosecution Strategy Guide

Executive Summary

Examiner BRADLEY, CHRISTINA works in Art Unit 1654 and has examined 926 patent applications in our dataset. With an allowance rate of 62.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 28 months.

Allowance Patterns

Examiner BRADLEY, CHRISTINA's allowance rate of 62.6% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BRADLEY, CHRISTINA receive 1.44 office actions before reaching final disposition. This places the examiner in the 33% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BRADLEY, CHRISTINA is 28 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +32.0% benefit to allowance rate for applications examined by BRADLEY, CHRISTINA. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 27.3% of applications are subsequently allowed. This success rate is in the 37% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 53.3% of cases where such amendments are filed. This entry rate is in the 75% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 34% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 87.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 58.3% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 15.6% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.0% of allowed cases (in the 57% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.